The Janssen Pharmaceutical Companies announced the acquisition of all rights to Bermekimab, along with certain employees, from XBiotech Inc., for $750 million. The Janssen Pharmaceutical
Please fill our short form.
Company Name (required)
Your Name (required)
Designation (required)
Number (required)
Your Email (required)